The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective trial of elemental enteral feeding in patients with pancreatic cancer cachexia (PANCAX-1).
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis; Perthera; Perthera; Perthera; Perthera
Research Funding - Ipsen; Ipsen; Ipsen; Ipsen
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme
 
Gillian Gresham
No Relationships to Disclose
 
Haesoo Kim
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Pfizer; Pfizer; Pfizer; Pfizer
 
Michelle Guan
No Relationships to Disclose
 
Jar-Yee Liu
No Relationships to Disclose
 
Brian Minton
No Relationships to Disclose
 
Diane Bhuiyan
No Relationships to Disclose
 
Ruby Langeslay
No Relationships to Disclose
 
Andre Rogatko
No Relationships to Disclose
 
Jun Gong
Honoraria - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants; Clinical Congress Consultants
 
Veronica Placencio-Hickok
Patents, Royalties, Other Intellectual Property - Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst); Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst)